Arylazopyrazole-Based Photoswitchable Inhibitors Selective for Escherichia coli Dihydrofolate Reductase

ACS Chem Biol. 2023 Feb 17;18(2):340-346. doi: 10.1021/acschembio.2c00749. Epub 2023 Jan 20.

Abstract

Selective inhibitors of Escherichia coli dihydrofolate reductase (eDHFR) are crucial chemical biology tools that have widespread clinical applications. We developed a set of eDHFR-selective photoswitchable inhibitors by derivatizing the structure of our previously reported methotrexate (MTX) azolog, azoMTX. Substitution of the skeletal p-phenylene group of azoMTX with bulky bis-alkylated arylazopyrazole moieties significantly increased its selectivity toward eDHFR over human DHFR. Owing to the physical properties of arylazopyrazoles, the new ligands exhibited nearly complete Z-to-E photoconversion and high thermostability of Z-isomers. In addition, real-time photoreversible control of eDHFR activity was achieved by alternatively switching the illumination light wavelengths.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Escherichia coli*
  • Humans
  • Methotrexate / chemistry
  • Methotrexate / pharmacology
  • Tetrahydrofolate Dehydrogenase* / chemistry

Substances

  • Tetrahydrofolate Dehydrogenase
  • Methotrexate